Vertex Pharmaceuticals Inc (VRTX) stock
VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3028% above fair value
$542.62−4.41 (-0.81%)
Close on Nov 12, 2026Market cap $137.53BP/E 31.6Yield –
Vertex Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Vertex Pharmaceuticals's total assets was $27.42B at Jun 30, 2026. For fiscal 2025 it was $25.64B, up 13.8% from the year before. Over ten years it grew 26.2% a year on average. The highest annual figure on record is $25.64B in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.64B | +13.8% |
| FY2024 | Dec 31, 2024 | $22.53B | -0.9% |
| FY2023 | Dec 31, 2023 | $22.73B | +25.2% |
| FY2022 | Dec 31, 2022 | $18.15B | +35.1% |
| FY2021 | Dec 31, 2021 | $13.43B | +14.3% |
| FY2020 | Dec 31, 2020 | $11.75B | +41.3% |
| FY2019 | Dec 31, 2019 | $8.32B | +33.2% |
| FY2018 | Dec 31, 2018 | $6.25B | +76.1% |
| FY2017 | Dec 31, 2017 | $3.55B | +22.4% |
| FY2016 | Dec 31, 2016 | $2.90B | +15.9% |
| FY2015 | Dec 31, 2015 | $2.50B | +7.0% |
| FY2014 | Dec 31, 2014 | $2.33B | +0.7% |
| FY2013 | Dec 31, 2013 | $2.32B | -16.0% |
| FY2012 | Dec 31, 2012 | $2.76B | +25.2% |
| FY2011 | Dec 31, 2011 | $2.20B | +27.8% |
| FY2010 | Dec 31, 2010 | $1.73B | -11.8% |
| FY2009 | Dec 31, 2009 | $1.96B | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $27.42B | +14.1% |
| Q1 FY2026 | Mar 31, 2026 | $26.48B | +15.8% |
| Q4 FY2025 | Dec 31, 2025 | $25.64B | +13.8% |
| Q3 FY2025 | Sep 30, 2025 | $24.86B | +11.8% |
| Q2 FY2025 | Jun 30, 2025 | $24.04B | +19.4% |
| Q1 FY2025 | Mar 31, 2025 | $22.88B | -4.3% |
| Q4 FY2024 | Dec 31, 2024 | $22.53B | -0.9% |
| Q3 FY2024 | Sep 30, 2024 | $22.24B | +2.4% |
| Q2 FY2024 | Jun 30, 2024 | $20.13B | -1.1% |
| Q1 FY2024 | Mar 31, 2024 | $23.92B | +26.1% |
| Q4 FY2023 | Dec 31, 2023 | $22.73B | +25.2% |
| Q3 FY2023 | Sep 30, 2023 | $21.73B | +30.0% |
| Q2 FY2023 | Jun 30, 2023 | $20.35B | +30.6% |
| Q1 FY2023 | Mar 31, 2023 | $18.97B | +33.1% |
| Q4 FY2022 | Dec 31, 2022 | $18.15B | +35.1% |
| Q3 FY2022 | Sep 30, 2022 | $16.71B | +32.4% |
| Q2 FY2022 | Jun 30, 2022 | $15.58B | +27.5% |
| Q1 FY2022 | Mar 31, 2022 | $14.26B | +17.7% |
| Q4 FY2021 | Dec 31, 2021 | $13.43B | +14.3% |
| Q3 FY2021 | Sep 30, 2021 | $12.62B | +11.7% |
| Q2 FY2021 | Jun 30, 2021 | $12.22B | +19.6% |
| Q1 FY2021 | Mar 31, 2021 | $12.12B | +36.2% |
| Q4 FY2020 | Dec 31, 2020 | $11.75B | +41.3% |
| Q3 FY2020 | Sep 30, 2020 | $11.30B | +50.4% |
| Q2 FY2020 | Jun 30, 2020 | $10.22B | +45.3% |
| Q1 FY2020 | Mar 31, 2020 | $8.89B | +35.9% |
| Q4 FY2019 | Dec 31, 2019 | $8.32B | +33.2% |
| Q3 FY2019 | Sep 30, 2019 | $7.51B | +62.6% |
| Q2 FY2019 | Jun 30, 2019 | $7.03B | +62.2% |
| Q1 FY2019 | Mar 31, 2019 | $6.54B | +65.5% |
| Q4 FY2018 | Dec 31, 2018 | $6.25B | +76.1% |
| Q3 FY2018 | Sep 30, 2018 | $4.62B | +44.5% |
| Q2 FY2018 | Jun 30, 2018 | $4.34B | +32.0% |
| Q1 FY2018 | Mar 31, 2018 | $3.95B | +34.1% |
| Q4 FY2017 | Dec 31, 2017 | $3.55B | +22.4% |
| Q3 FY2017 | Sep 30, 2017 | $3.20B | +22.6% |
| Q2 FY2017 | Jun 30, 2017 | $3.29B | – |
| Q1 FY2017 | Mar 31, 2017 | $2.95B | – |
| Q4 FY2016 | Dec 31, 2016 | $2.90B | – |
| Q3 FY2016 | Sep 30, 2016 | $2.61B | – |
See a number that looks wrong?